Related Experiment Video
Updated: Sep 12, 2025

Author Spotlight: Advancing Prostate Cancer Research Through Improved Tissue Sampling and Biobanking
Published on: November 17, 2023
[Diagnostic value of hematological parameters for prostate cancer in patients with gray-zone prostate-specific
Peng Ge1, Yu-Xin Zheng2, Zi-Rong Yan1
1Department of Urology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
Objective:
To evaluate the diagnostic value of hematological parameters for PCa with prostate-specific antigen (PSA) of 4-10 μg/L and construct a risk-stratification model with these parameters.
Methods:
We retrospectively analyzed the data on the males undergoing the initial prostatic biopsy in the Affiliated Hospital of Xuzhou Medical University with PSA of 4-10 μg/L from March 2010 to April 2021. According to the results of biopsy, we classified the patients into a PCa and a non-PCa group, and compared the hematological parameters between the two groups. We performed univariate and multivariate logistic regression analyses, identified the independent risk factors for PCa, constructed a risk-stratification model for the prediction of PCa and evaluated its efficiency.
Results:
A total of 415 cases were included in this study, 107 (25.8%) in the PCa and 308 (74.2%) in the non-PCa group. Compared with the non-PCa males, the PCa patients showed a significantly older age, higher ratios of neutrophil to lymphocyte and platelet to lymphocyte, systemic immune-inflammation index (SII), red blood cell distribution width and cystatin C (CysC) level (all P<0.05), but lower red blood cell count and hemoglobin and free/total PSA (f/tPSA) levels (all P<0.05). Multivariate logistic regression analysis indicated that age, f/tPSA, SII and CysC were independent risk factors for the prediction of PCa (all P<0.05). Five prediction models were constructed based on the above risk factors, and the area under the ROC curve (AUC) of the four-parameter (age+f/tPSA+SII+CysC) model was 0.745 (95% CI: 0.694-0.796), significantly higher than those of the other models (P<0.05). A risk-stratification model (low-, intermediate-, and high-risk) was also constructed based on the total nomogram scores, which showed a comparable performance to that of the Prostate Imaging Reporting and Data System (PI-RADS) for the prediction of PCa (AUC: 0.727 [95% CI: 0.650-0.804] vs 0.734 [95% CI: 0.658-0.811]). However, the prediction rate by the risk-stratification model was evidently higher in the low-risk males than in those with low PI-RADS scores (1-2) (39.4% vs 22.2%).
Conclusion:
SII and CysC are independent risk factors for the prediction of PCa in patients with gray-zone PSA levels. The risk-stratification model based on age, SII, CysC and f/tPSA is comparable to PI-RADS in the diagnostic efficiency of PCa, with an even higher prediction rate in low-risk patients than in those with low PI-RADS scores, and contributive to precision screening and reduction of excessive biopsies in the diagnosis of PCa with gray-zone PSA.

